Browne SE - Search Results

1

Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.

Smith KM, Browne SE, Jayaraman S, Bleickardt CJ, Hodge LM, Lis E, Yao L, Rittle SL, Innocent N, Mullins DE, Boykow G, Reynolds IJ, Hill D, Parker EM, Hodgson RA. Smith KM, et al. Among authors: browne se. Eur J Pharmacol. 2014 Apr 5;728:31-8. doi: 10.1016/j.ejphar.2014.01.052. Epub 2014 Jan 31. Eur J Pharmacol. 2014. PMID: 24486705

2

PISA, a novel pharmacodynamic assay for assessing poly(ADP-ribose) polymerase (PARP) activity in situ.

Lubbers LS, Rowe BA, Hodge LM, Browne SE, Gundersdorf R, Jones P, Hess FJ, Reynolds IJ. Lubbers LS, et al. Among authors: browne se. J Pharmacol Toxicol Methods. 2010 May-Jun;61(3):319-28. doi: 10.1016/j.vascn.2010.01.012. Epub 2010 Feb 2. J Pharmacol Toxicol Methods. 2010. PMID: 20132901

3

A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease.

Le Poul E, Boléa C, Girard F, Poli S, Charvin D, Campo B, Bortoli J, Bessif A, Luo B, Koser AJ, Hodge LM, Smith KM, DiLella AG, Liverton N, Hess F, Browne SE, Reynolds IJ. Le Poul E, et al. Among authors: browne se. J Pharmacol Exp Ther. 2012 Oct;343(1):167-77. doi: 10.1124/jpet.112.196063. Epub 2012 Jul 11. J Pharmacol Exp Ther. 2012. PMID: 22787118

4

Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders.

Kalinichev M, Le Poul E, Boléa C, Girard F, Campo B, Fonsi M, Royer-Urios I, Browne SE, Uslaner JM, Davis MJ, Raber J, Duvoisin R, Bate ST, Reynolds IJ, Poli S, Celanire S. Kalinichev M, et al. Among authors: browne se. J Pharmacol Exp Ther. 2014 Sep;350(3):495-505. doi: 10.1124/jpet.114.214437. Epub 2014 Jun 19. J Pharmacol Exp Ther. 2014. PMID: 24947466 Free PMC article.

5

Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators.

Ramirez AD, Gotter AL, Fox SV, Tannenbaum PL, Yao L, Tye SJ, McDonald T, Brunner J, Garson SL, Reiss DR, Kuduk SD, Coleman PJ, Uslaner JM, Hodgson R, Browne SE, Renger JJ, Winrow CJ. Ramirez AD, et al. Among authors: browne se. Front Neurosci. 2013 Dec 24;7:254. doi: 10.3389/fnins.2013.00254. eCollection 2013. Front Neurosci. 2013. PMID: 24399926 Free PMC article.

6

Discovery, Optimization, and Biological Characterization of 2,3,6-Trisubstituted Pyridine-Containing M₄ Positive Allosteric Modulators.

Schubert JW, Harrison ST, Mulhearn J, Gomez R, Tynebor R, Jones K, Bunda J, Hanney B, Wai JM, Cox C, McCauley JA, Sanders JM, Magliaro B, O'Brien J, Pajkovic N, Huszar Agrapides SL, Taylor A, Gotter A, Smith SM, Uslaner J, Browne S, Risso S, Egbertson M. Schubert JW, et al. ChemMedChem. 2019 May 6;14(9):943-951. doi: 10.1002/cmdc.201900088. Epub 2019 Mar 28. ChemMedChem. 2019. PMID: 30920765

7

Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease.

Saydoff JA, Garcia RA, Browne SE, Liu L, Sheng J, Brenneman D, Hu Z, Cardin S, Gonzalez A, von Borstel RW, Gregorio J, Burr H, Beal MF. Saydoff JA, et al. Among authors: browne se. Neurobiol Dis. 2006 Dec;24(3):455-65. doi: 10.1016/j.nbd.2006.08.011. Epub 2006 Sep 29. Neurobiol Dis. 2006. PMID: 17011205

8

Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models.

Browne SE. Browne SE. Ann N Y Acad Sci. 2008 Dec;1147:358-82. doi: 10.1196/annals.1427.018. Ann N Y Acad Sci. 2008. PMID: 19076457 Review.

9

Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease.

Ferrante RJ, Ryu H, Kubilus JK, D'Mello S, Sugars KL, Lee J, Lu P, Smith K, Browne S, Beal MF, Kristal BS, Stavrovskaya IG, Hewett S, Rubinsztein DC, Langley B, Ratan RR. Ferrante RJ, et al. J Neurosci. 2004 Nov 17;24(46):10335-42. doi: 10.1523/JNEUROSCI.2599-04.2004. J Neurosci. 2004. PMID: 15548647 Free PMC article.

10

Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment.

Albers DS, Augood SJ, Park LC, Browne SE, Martin DM, Adamson J, Hutton M, Standaert DG, Vonsattel JP, Gibson GE, Beal MF. Albers DS, et al. Among authors: browne se. J Neurochem. 2000 Feb;74(2):878-81. doi: 10.1046/j.1471-4159.2000.740878.x. J Neurochem. 2000. PMID: 10646541 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters